Evidence map›Paper›PMID 36327615›Full record

ArticleJournal of substance abuse treatment2023

Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.

Rosanna Smart, Joo Yeon Kim, Susan Kennedy, Lu Tang, Lindsay Allen, Dushka Crane, Aimee Mack, Shamis Mohamoud, Nathan Pauly, Rosa Perez and 1 more

Abstract read
In one paragraph

Article in Journal of substance abuse treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Prenatal substance use and mental health comorbidities predict continued use.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2025
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rosanna SmartDrug Policy Research Center, RAND Corporation, 1776 Main Street, PO Box 2138, Santa Monica, CA 90407-2138, United States of America. Electronic address: rsmart@rand.org.
Joo Yeon KimDepartment of Health Policy and Management, University of Pittsburgh, 130 DeSoto Street, Crabtree Hall A635, Pittsburgh, PA 15261, United States of America. Electronic address: jykim@pitt.edu.
Susan KennedyAcademyHealth, 1666 K Street NW, Suite 1100, Washington, DC 20006, United States of America. Electronic address: susan.kennedy@academyhealth.org.
Lu TangDepartment of Biostatistics, University of Pittsburgh, 130 DeSoto Street, Pittsburgh, PA 15261, United States of America. Electronic address: LUTANG@pitt.edu.
Lindsay AllenDepartment of Emergency Medicine, Buehler Center for Health Policy & Economics, Northwestern University, 750 N. Lake Shore Drive, Evanston, IL 60611, United States of America. Electronic address: lindsay.allen@northwestern.edu.
Dushka CraneGovernment Resource Center, The Ohio State University, 150 Pressey Hall, 1070 Carmack Road, Columbus, OH 43210, United States of America. Electronic address: Dushka.Crane@osumc.edu.
Aimee MackGovernment Resource Center, The Ohio State University, 150 Pressey Hall, 1070 Carmack Road, Columbus, OH 43210, United States of America. Electronic address: Aimee.Mack@osumc.edu.
Shamis MohamoudThe Hilltop Institute, University of Maryland Baltimore County, Sondheim Hall, Third Floor, 1000 Hilltop Circle, Baltimore, MD 21250, United States of America. Electronic address: smohamoud@hilltop.umbc.edu.
Nathan PaulyManatt Health Strategies, 151 N Franklin Street, Suite 2600, Chicago, IL 60606, United States of America. Electronic address: NPauly@manatt.com.
Rosa PerezThe Hilltop Institute, University of Maryland Baltimore County, Sondheim Hall, Third Floor, 1000 Hilltop Circle, Baltimore, MD 21250, United States of America. Electronic address: rperez@hilltop.umbc.edu.
Julie DonohueDepartment of Health Policy and Management, University of Pittsburgh, 130 DeSoto Street, Crabtree Hall A635, Pittsburgh, PA 15261, United States of America. Electronic address: jdonohue@pitt.edu.

Funding

Scientific and Technical CoreP2CHD041022 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Martha Jane Bailey · 2016 to 2026
$6.9M
Examining the quality of opioid use disorder treatment in a Medicaid research networkR01DA048029 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DONOHUE, JULIE MARIE · 2019 to 2021
$3.5M
NICHD NIH HHS P2C HD041022NIDA NIH HHS R01 DA048029
6 · The paper itself

Abstract

introductionThe opioid crisis is transitioning to a polydrug crisis, and individuals with co-occurring substance use disorder (SUDs) often have unique clinical characteristics and contextual barriers that influence treatment needs, engagement in treatment, complexity of treatment planning, and treatment retention.

methodsUsing Medicaid data for 2017-2018 from four states participating in a distributed research network, this retrospective cohort study documents the prevalence of specific types of co-occurring SUD among Medicaid enrollees with an opioid use disorder (OUD) diagnosis, and assesses the extent to which different SUD presentations are associated with differential patterns of MOUD and psychosocial treatments.

resultsWe find that more than half of enrollees with OUD had a co-occurring SUD, and the most prevalent co-occurring SUD was for "other psychoactive substances", indicated among about one-quarter of enrollees with OUD in each state. We also find some substantial gaps in MOUD treatment receipt and engagement for individuals with OUD and a co-occurring SUD, a group representing more than half of individuals with OUD. In most states, enrollees with OUD and alcohol, cannabis, or amphetamine use disorder are significantly less likely to receive MOUD compared to enrollees with OUD only. In contrast, enrollees with OUD and other psychoactive SUD were significantly more likely to receive MOUD treatment. Conditional on MOUD receipt, enrollees with co-occurring SUDs had 10 % to 50 % lower odds of having a 180-day period of continuous MOUD treatment, an important predictor of better patient outcomes. Associations with concurrent receipt of MOUD and behavioral counseling were mixed across states and varied depending on co-occurring SUD type.

conclusionsOverall, ongoing progress toward increasing access to and quality of evidence-based treatment for OUD requires further efforts to ensure that individuals with co-occurring SUDs are engaged and retained in effective treatment. As the opioid crisis evolves, continued changes in drug use patterns and populations experiencing harms may necessitate new policy approaches that more fully address the complex needs of a growing population of individuals with OUD and other types of SUD.

Indexed as

BuprenorphineOpioid-Related DisordersAnalgesics, OpioidHumansMedicaidOpiate Substitution TreatmentPrevalenceRetrospective StudiesUnited StatesAnalgesics, OpioidBuprenorphineMedicaidMedication treatment for opioid use disorderPolysubstance useSubstance use disorder

Identifiers

PMID36327615
PMCPMC10664516

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.